ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

safusidenib

Also written as “Safusidenib”, “DS-1001b” and “AB-218 capsule”.

Its studies are mostly in Glioma · Oligodendroglioma · Astrocytoma · Cholangiocarcinoma, led by 2 companies.

Drug pageSafusidenib: every studyAll 7 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Mar 13, 20226 company-led studies, 4 open or runningNext primary completion: Dec 1, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Nuvation Bioits history only43 open or runningphase 3since Mar 13, 2022Mar 13, 2022Dec 1, 2028phase 3 · NCT05303519
Daiichi Sankyo21 open or runningphase 2since Jun 29, 2020Jan 18, 2017none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Daiichi Sankyo only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jan 18, 2017First study: phase 1 study in GliomaFirst studyNCT03030066 · 47 enrolled · Japan
  2. Jun 29, 2020Phase 2 study in GliomaNCT04458272 · 25 enrolled · Japan
  3. Jan 25, 2022Named safusidenibINNProposed as its International Nonproprietary Name in WHO's List 126

TargetBeta

IDH1 →read by rule
“An orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1; IDH-1; IDH1 [NADP+] soluble) mutant forms, including substitution mutations at the arginine in position 132, IDH1(R132) (IDH1-R132), ”NCIt, by rule
“Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor; Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor”ChEMBL 37, by rule

Other programs on IDH1

ProgramCompanyFurthest phaseStudies
olutasidenibruleRigel Pharmaceuticalsphase 45
ivosidenibruleAgios Pharmaceuticalsphase 313
vorasidenibruleAgios Pharmaceuticalsphase 312
ranosidenibruleHUTCHMEDphase 37
IDH1 Inhibitor TQB3454Sino Biopharmaceuticalphase 35

Studies

All 2 Daiichi Sankyo leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04458272Glioma · Japan2Active, not recruitingMar 10, 202325
NCT03030066Glioma · Japan1CompletedJan 31, 202147

How it is read

Names in the registry

  • “Safusidenib”, 2 entries
  • “DS-1001b”, 2 entries
  • “safusidenib”, 1 entry
  • “AB-218 capsule”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.